
Melinta chief John Johnson jumps ship — with the chairman — from another troubled antibiotics play
Just 9 months after taking the reins at Melinta, the experienced biotech exec John Johnson is whirling back out through the revolving door to the C suite at the troubled antibiotics company.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.